Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
- PMID: 17369375
- PMCID: PMC1856849
- DOI: 10.1136/gut.2005.088732
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
Abstract
The main goal of treatment for Crohn's disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best remission. It has been shown by many studies that the long-term outcome of these diseases is not influenced by standard treatments and that the need for surgery is not decreasing in this population over the years. There is recent evidence that with immunosuppression and treatment with infliximab long-term healing of the bowel can be achieved and that this affects the outcome of both Crohn's disease and ulcerative colitis. We propose that future studies should focus on healing and disease course as primary outcome measures.
Conflict of interest statement
Competing interests: None.
Similar articles
-
Review article: Infliximab therapy for inflammatory bowel disease--seven years on.Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63. doi: 10.1111/j.1365-2036.2006.02786.x. Aliment Pharmacol Ther. 2006. PMID: 16441465 Review.
-
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.
-
Medical treatment of inflammatory bowel diseases.Curr Opin Gastroenterol. 2005 Jul;21(4):443-7. Curr Opin Gastroenterol. 2005. PMID: 15930985 Review.
-
Mucosal healing with anti-TNF antibodies.Digestion. 2012;86 Suppl 1:16-22. doi: 10.1159/000341957. Epub 2012 Oct 5. Digestion. 2012. PMID: 23051722 Review.
-
[Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].Z Gastroenterol. 2002 Apr;40 Suppl 1:S90-S1. doi: 10.1055/s-2002-23620. Z Gastroenterol. 2002. PMID: 11930299 German.
Cited by
-
Role of endoscopy in inflammatory bowel disease.Gastroenterol Rep (Oxf). 2018 May;6(2):75-82. doi: 10.1093/gastro/goy006. Epub 2018 Mar 9. Gastroenterol Rep (Oxf). 2018. PMID: 29780594 Free PMC article. Review.
-
Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease.Intest Res. 2017 Jul;15(3):311-317. doi: 10.5217/ir.2017.15.3.311. Epub 2017 Jun 12. Intest Res. 2017. PMID: 28670227 Free PMC article. Review.
-
Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis.World J Gastroenterol. 2010 Apr 21;16(15):1908-15. doi: 10.3748/wjg.v16.i15.1908. World J Gastroenterol. 2010. PMID: 20397271 Free PMC article.
-
Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution.Br J Pharmacol. 2018 Dec;175(23):4353-4370. doi: 10.1111/bph.14494. Epub 2018 Oct 15. Br J Pharmacol. 2018. PMID: 30184260 Free PMC article.
-
Mucosal healing and inflammatory bowel disease: Therapeutic implications and new targets.World J Gastroenterol. 2023 Feb 21;29(7):1157-1172. doi: 10.3748/wjg.v29.i7.1157. World J Gastroenterol. 2023. PMID: 36926666 Free PMC article. Review.
References
-
- D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo‐) colitis with azathioprine. Gastrointest Endosc 199950667–671. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources